CONMED Corporation $CNMD Stock Holdings Decreased by Kempner Capital Management Inc.

Kempner Capital Management Inc. lessened its stake in CONMED Corporation (NYSE:CNMD) by 87.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,258 shares of the company’s stock after selling 43,296 shares during the quarter. Kempner Capital Management Inc.’s holdings in CONMED were worth $252,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Kelleher Financial Advisors acquired a new position in CONMED in the third quarter worth about $28,000. Quarry LP raised its stake in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after buying an additional 617 shares in the last quarter. Huntington National Bank raised its stake in CONMED by 111.8% during the third quarter. Huntington National Bank now owns 883 shares of the company’s stock valued at $42,000 after buying an additional 466 shares in the last quarter. State of Wyoming bought a new position in CONMED during the 3rd quarter worth approximately $52,000. Finally, GAMMA Investing LLC lifted its holdings in CONMED by 14.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,770 shares of the company’s stock worth $83,000 after buying an additional 228 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CNMD. Wells Fargo & Company upgraded CONMED to a “hold” rating in a research report on Wednesday, March 18th. Wall Street Zen cut CONMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a report on Thursday, January 29th. Bank of America lowered their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a report on Wednesday, January 21st. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $50.17.

CONMED Stock Down 0.3%

Shares of CONMED stock opened at $36.51 on Wednesday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of 24.18, a PEG ratio of 1.61 and a beta of 0.91. CONMED Corporation has a twelve month low of $35.37 and a twelve month high of $61.25. The company has a current ratio of 2.14, a quick ratio of 1.01 and a debt-to-equity ratio of 0.81. The business’s 50 day simple moving average is $40.96 and its 200-day simple moving average is $43.33.

CONMED (NYSE:CNMD) last released its quarterly earnings data on Wednesday, January 28th. The company reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.11. The business had revenue of $373.20 million during the quarter, compared to analyst estimates of $366.88 million. CONMED had a return on equity of 14.23% and a net margin of 3.42%.The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.34 EPS. Equities research analysts forecast that CONMED Corporation will post 4.35 earnings per share for the current year.

CONMED Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.